Logo image of SSKN

STRATA SKIN SCIENCES INC (SSKN) Stock Fundamental Analysis

NASDAQ:SSKN - Nasdaq - US86272A3059 - Common Stock - Currency: USD

2.46  -0.04 (-1.6%)

Fundamental Rating

2

SSKN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. SSKN has a bad profitability rating. Also its financial health evaluation is rather negative. SSKN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SSKN had negative earnings in the past year.
In the past year SSKN had a positive cash flow from operations.
In the past 5 years SSKN always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: SSKN reported negative operating cash flow in multiple years.
SSKN Yearly Net Income VS EBIT VS OCF VS FCFSSKN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -27.90%, SSKN is in line with its industry, outperforming 46.03% of the companies in the same industry.
SSKN has a Return On Equity of -202.86%. This is in the lower half of the industry: SSKN underperforms 75.13% of its industry peers.
Industry RankSector Rank
ROA -27.9%
ROE -202.86%
ROIC N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
SSKN Yearly ROA, ROE, ROICSSKN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

SSKN has a Gross Margin (56.85%) which is comparable to the rest of the industry.
SSKN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SSKN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.85%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
SSKN Yearly Profit, Operating, Gross MarginsSSKN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

SSKN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SSKN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SSKN has less shares outstanding
SSKN has a worse debt/assets ratio than last year.
SSKN Yearly Shares OutstandingSSKN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
SSKN Yearly Total Debt VS Total AssetsSSKN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

SSKN has an Altman-Z score of -8.91. This is a bad value and indicates that SSKN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.91, SSKN is not doing good in the industry: 76.19% of the companies in the same industry are doing better.
SSKN has a Debt/Equity ratio of 3.06. This is a high value indicating a heavy dependency on external financing.
SSKN has a Debt to Equity ratio of 3.06. This is amonst the worse of the industry: SSKN underperforms 86.77% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF N/A
Altman-Z -8.91
ROIC/WACCN/A
WACC9.73%
SSKN Yearly LT Debt VS Equity VS FCFSSKN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

SSKN has a Current Ratio of 1.13. This is a normal value and indicates that SSKN is financially healthy and should not expect problems in meeting its short term obligations.
SSKN has a worse Current ratio (1.13) than 85.71% of its industry peers.
A Quick Ratio of 0.98 indicates that SSKN may have some problems paying its short term obligations.
With a Quick ratio value of 0.98, SSKN is not doing good in the industry: 79.37% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 0.98
SSKN Yearly Current Assets VS Current LiabilitesSSKN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.93% over the past year.
SSKN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.60%.
The Revenue has been growing slightly by 1.22% on average over the past years.
EPS 1Y (TTM)3.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.73%
Revenue 1Y (TTM)0.6%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%54.25%

3.2 Future

SSKN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.39% yearly.
The Revenue is expected to grow by 8.49% on average over the next years. This is quite good.
EPS Next Y61.29%
EPS Next 2Y35.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year7.56%
Revenue Next 2Y8.49%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SSKN Yearly Revenue VS EstimatesSSKN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M
SSKN Yearly EPS VS EstimatesSSKN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SSKN. In the last year negative earnings were reported.
Also next year SSKN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SSKN Price Earnings VS Forward Price EarningsSSKN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SSKN Per share dataSSKN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as SSKN's earnings are expected to grow with 35.39% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.39%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SSKN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRATA SKIN SCIENCES INC

NASDAQ:SSKN (5/9/2025, 4:00:25 PM)

2.46

-0.04 (-1.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-28 2025-04-28/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners29.24%
Inst Owner Change-7.4%
Ins Owners1.59%
Ins Owner Change0%
Market Cap10.26M
Analysts85
Price Target10.2 (314.63%)
Short Float %0.04%
Short Ratio0.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-144.61%
Min EPS beat(2)-271.14%
Max EPS beat(2)-18.09%
EPS beat(4)1
Avg EPS beat(4)-61.36%
Min EPS beat(4)-271.14%
Max EPS beat(4)95.8%
EPS beat(8)2
Avg EPS beat(8)-84.65%
EPS beat(12)5
Avg EPS beat(12)-45.71%
EPS beat(16)8
Avg EPS beat(16)-23.27%
Revenue beat(2)2
Avg Revenue beat(2)2.82%
Min Revenue beat(2)1.03%
Max Revenue beat(2)4.61%
Revenue beat(4)3
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-4.2%
Max Revenue beat(4)11.4%
Revenue beat(8)3
Avg Revenue beat(8)-4.43%
Revenue beat(12)6
Avg Revenue beat(12)-0.55%
Revenue beat(16)8
Avg Revenue beat(16)-0.1%
PT rev (1m)0%
PT rev (3m)-37.5%
EPS NQ rev (1m)-13.41%
EPS NQ rev (3m)-17.27%
EPS NY rev (1m)-4.4%
EPS NY rev (3m)1.45%
Revenue NQ rev (1m)-5.66%
Revenue NQ rev (3m)-12.75%
Revenue NY rev (1m)-0.76%
Revenue NY rev (3m)-3.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.31
P/FCF N/A
P/OCF 54.56
P/B 2.06
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.69
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)0.05
OCFY1.83%
SpS8.05
BVpS1.19
TBVpS-0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.9%
ROE -202.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.85%
FCFM N/A
ROA(3y)-21.43%
ROA(5y)-15.91%
ROE(3y)-104.54%
ROE(5y)-68.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.95%
GM growth 5Y-2.39%
F-Score4
Asset Turnover0.93
Health
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.83%
Cap/Sales 4.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 0.98
Altman-Z -8.91
F-Score4
WACC9.73%
ROIC/WACCN/A
Cap/Depr(3y)60.99%
Cap/Depr(5y)68.15%
Cap/Sales(3y)9.91%
Cap/Sales(5y)10.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.73%
EPS Next Y61.29%
EPS Next 2Y35.39%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.6%
Revenue growth 3Y3.83%
Revenue growth 5Y1.22%
Sales Q2Q%54.25%
Revenue Next Year7.56%
Revenue Next 2Y8.49%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year154.53%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y136.22%
OCF growth 3Y-50.07%
OCF growth 5Y-39.02%